Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-05-25 DOI:10.1016/j.cllc.2024.05.008

{"title":"Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report","authors":"","doi":"10.1016/j.cllc.2024.05.008","DOIUrl":null,"url":null,"abstract":"<div><ul><li>•Tepotinib, a potent, highly selective, once-daily, oral MET tyrosine kinase inhibitor, is approved in multiple countries for the treatment of advanced/metastatic METex14 skipping NSCLC and can be used in patients with mild-moderate renal impairment without dose adjustment. However, data in severe renal impairment are lacking.</li><li>•We report the feasibility of using the standard dose of tepotinib (500 mg; 450 mg active moiety) in a patient with advanced METex14 skipping NSCLC with end-stage renal disease undergoing hemodialysis, who attained disease control, with only mild adverse events that did not necessitate dose adjustment.</li><li>•Use of the standard dose was supported by tepotinib plasma concentration measurements, which fell within the expected range for a typical patient with NSCLC predicted using a population pharmacokinetic model and indicated no clinically relevant drug loss during dialysis.</li></ul></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1525730424001098/pdfft?md5=14101f14756f4deae6004a00cbe71a77&pid=1-s2.0-S1525730424001098-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1525730424001098","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

•
Tepotinib, a potent, highly selective, once-daily, oral MET tyrosine kinase inhibitor, is approved in multiple countries for the treatment of advanced/metastatic METex14 skipping NSCLC and can be used in patients with mild-moderate renal impairment without dose adjustment. However, data in severe renal impairment are lacking.
•
We report the feasibility of using the standard dose of tepotinib (500 mg; 450 mg active moiety) in a patient with advanced METex14 skipping NSCLC with end-stage renal disease undergoing hemodialysis, who attained disease control, with only mild adverse events that did not necessitate dose adjustment.
•
Use of the standard dose was supported by tepotinib plasma concentration measurements, which fell within the expected range for a typical patient with NSCLC predicted using a population pharmacokinetic model and indicated no clinically relevant drug loss during dialysis.

查看原文本刊更多论文

特泊替尼用于因肾衰竭而同时接受血液透析的携带 MET 第 14 号外显子的晚期非小细胞肺癌患者：病例报告

-特泊替尼是一种强效、高选择性、每日一次的口服MET酪氨酸激酶抑制剂，已在多个国家获批用于治疗晚期/转移性METex14跳跃NSCLC，可用于轻中度肾功能损害患者，无需调整剂量。我们报告了在一名接受血液透析的晚期 METex14 跳过 NSCLC 终末期肾病患者身上使用标准剂量特泊替尼（500 毫克；450 毫克活性分子）的可行性，该患者病情得到控制，仅出现轻微不良反应，无需调整剂量。-特泊替尼血浆浓度的测量结果支持了标准剂量的使用，其浓度在使用群体药代动力学模型预测的典型 NSCLC 患者的预期范围内，并表明在透析过程中没有临床相关的药物流失。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567